RainDance Technologies and Ambry Genetics have launched ADMESeq, a targeted sequencing panel that will sequence 242 genes involved with drug absorption, distribution, metabolism, and excretion.
Ambry Genetics will be the first authorized service provider for a new high-throughput target enrichment system being developed by RainDance Technologies, the companies announced last week.
By Justin Petrone
Growing demand for arrays designed to detect tumor copy-number changes is enticing more chip manufacturers to offer tools tailor-made for cancer research.
Ambry's StemArray is manufactured by Roche NimbleGen and enables researchers studying stem cells to detect genomic abnormalities that would ordinarily be missed by low-resolution karyotyping.
Ambry Genetics is now able to offer all Roche NimbleGen applications, the first of Roche NimbleGen's growing list of service providers to achieve such certification.
An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.
In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.
